GVT
MYGN icon

Genesee Valley Trust’s Myriad Genetics MYGN Stock Holding History

Genesee Valley Trust’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-31,907
Closed -$657K – 254
2016
Q3 		$657K Buy
31,907
+13,959
+78% +$354K 0.4% 83
2016
Q2 		$549K Buy
17,948
+3,844
+27% +$134K 0.36% 97
2016
Q1 		$528K Buy
14,104
+1,814
+15% +$68.4K 0.36% 95
2015
Q4 		$530K Sell
12,290
-4,873
-28% -$206K 0.35% 98
2015
Q3 		$643K Buy
17,163
+8,533
+99% +$303K 0.43% 77
2015
Q2 		$293K Buy
+8,630
New +$293K 0.19% 190
2014
Q1 		– Sell
-10,005
Closed -$210K – 328
2013
Q4 		$210K Buy
+10,005
New +$253K 0.14% 267

Other funds holding MYGN

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Genesee Valley Trust's MYGN Position: Q4 2016 in Review

Genesee Valley Trust sold out of Myriad Genetics (MYGN) in Q4 2016, closing a stake of 31,907 shares — an estimated $657K sold.

Genesee Valley Trust first reported a position in MYGN in Q4 2013 and held it in 7 quarters. The position peaked at $657K in Q3 2016. 223 funds tracked by Wall St. Rank hold MYGN as of Q4 2016.

  • Genesee Valley Trust reported no remaining Myriad Genetics position as of Q4 2016 after selling out during the quarter.
  • Genesee Valley Trust sold 31,907 Myriad Genetics shares in Q4 2016, an estimated $657K.
  • Genesee Valley Trust first reported a position in Myriad Genetics in Q4 2013 and held it in 7 quarters.
  • Genesee Valley Trust's Myriad Genetics position peaked at $657K in Q3 2016.
  • 223 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2016.

Based on Genesee Valley Trust's 13F filing for Q4 2016, filed 22 Feb 2017.